OncoMatch/Clinical Trials/NCT07835087
Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
Official title: Image-Guided Platform-Assisted Intraoperative and Postoperative Sentinel Lymph Node Retrieval in Early Gastric Cancer: A Prospective Randomized Controlled Trial
Is NCT07835087 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies Image-Guided Retrieval Specimen Platform for early gastric cancer.
Treatment: Image-Guided Retrieval Specimen Platform — This prospective, single-center, randomized controlled trial aims to evaluate the clinical effectiveness of an Image-Guided Platform assisted by a deep learning model for sentinel lymph node (SLN) retrieval in patients with early gastric cancer undergoing laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery (LECS-SNNS). A total of 36 eligible participants will be randomly assigned in a 1:1 ratio to either the Image-Guided Platform group or the Traditional Palpation group. Both groups will undergo standardized indocyanine green fluorescence-guided sentinel lymphatic basin dissection and initial retrieval of fluorescent sentinel lymph nodes. In the experimental group, the remaining sentinel lymphatic basin (SLB) tissue will be examined using the Image-Guided Platform, which integrates radiographic and optical imaging with a deep learning model to identify and localize suspected lymph nodes. In the control group, LN retrieval will be performed using traditional visual inspection and palpation. The primary objective is to determine whether Image-Guided Platform-assisted LN retrieval increases the total number of SLNs retrieved intraoperatively compared with Traditional Palpation. Secondary objectives include assessment of LN retrieval efficiency, pathological findings, additional LN identification during permanent pathological examination, concordance between intraoperative frozen-section and permanent pathological examination, and other procedural, pathological, technical, and clinical outcomes relevant to the feasibility and performance of the Image-Guided Platform and deep learning model.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT1N0M0
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: gastrointestinal surgery
Previous gastrointestinal surgery
Cannot have received: chemotherapy
Previous chemotherapy
Cannot have received: radiation therapy
Previous radiotherapy
Lab requirements
Blood counts
adequate bone marrow function to tolerate the planned surgical and perioperative management
Kidney function
adequate renal function to tolerate the planned surgical and perioperative management
Liver function
adequate hepatic function to tolerate the planned surgical and perioperative management
Cardiac function
adequate cardiac function to tolerate the planned surgical and perioperative management
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07835087 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gastrointestinal surgery, chemotherapy, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT1N0M0 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages